Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
Advances in Therapy|November 23, 2011
Multiple myeloma with extramedullary diseaseAlbert Oriol
Expert Review of Hematology|March 18, 2020
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myelomaAlbert Oriol
Medicina Clinica|December 18, 2013
[New drugs in the treatment of multiple myeloma]Albert Oriol, Cristina Motlló
Cancers|June 2, 2021
Current and Novel Alkylators in Multiple MyelomaFredrik Schjesvold, Albert Oriol
Hematology/Oncology Clinics of North America|October 15, 2009
Acute lymphoblastic leukemia in adolescents and young adultsJosep-Maria Ribera, Albert Oriol
Expert Review of Anticancer Therapy|May 17, 2023
First-line treatment of multiple myeloma in both transplant and non-transplant candidatesAlbert Oriol, Laura Abril, Gladys Ibarra
Expert Opinion on Biological Therapy|October 15, 2025
Belantamab mafodotin for the treatment of multiple myelomaAlbert Oriol, Gladys Ibarra, Jordi Loscos, et al.
Expert Review of Anticancer Therapy|December 24, 2019
Limited treatment options in refractory multiple myeloma: promising therapeutic developmentsAlbert Oriol, Laura Abril, Gladys Ibarra, et al.
Advances in Therapy|November 23, 2011
Extramedullary plasmacytomas in the context of multiple myelomaBeatriz Aguado, Belen Iñigo, Jose L Sastre, et al.
Therapeutic Advances in Hematology|June 9, 2021
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myelomaAlbert Oriol, Laura Abril, Anna Torrent, et al.
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
Advances in Therapy|November 23, 2011
Multiple myeloma with extramedullary diseaseAlbert Oriol
Expert Review of Hematology|March 18, 2020
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myelomaAlbert Oriol
Medicina Clinica|December 18, 2013
[New drugs in the treatment of multiple myeloma]Albert Oriol, Cristina Motlló
Cancers|June 2, 2021
Current and Novel Alkylators in Multiple MyelomaFredrik Schjesvold, Albert Oriol
Hematology/Oncology Clinics of North America|October 15, 2009
Acute lymphoblastic leukemia in adolescents and young adultsJosep-Maria Ribera, Albert Oriol
Expert Review of Anticancer Therapy|May 17, 2023
First-line treatment of multiple myeloma in both transplant and non-transplant candidatesAlbert Oriol, Laura Abril, Gladys Ibarra
Expert Opinion on Biological Therapy|October 15, 2025
Belantamab mafodotin for the treatment of multiple myelomaAlbert Oriol, Gladys Ibarra, Jordi Loscos, et al.
Expert Review of Anticancer Therapy|December 24, 2019
Limited treatment options in refractory multiple myeloma: promising therapeutic developmentsAlbert Oriol, Laura Abril, Gladys Ibarra, et al.
Advances in Therapy|November 23, 2011
Extramedullary plasmacytomas in the context of multiple myelomaBeatriz Aguado, Belen Iñigo, Jose L Sastre, et al.
Therapeutic Advances in Hematology|June 9, 2021
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myelomaAlbert Oriol, Laura Abril, Anna Torrent, et al.
Pageof 25